Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1539-1544
Published online before print April 20, 2006, doi: 10.1161/01.ATV.0000223143.88128.19
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/7/1539    most recent
01.ATV.0000223143.88128.19v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuhlencordt, P. J.
Right arrow Articles by Ertl, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuhlencordt, P. J.
Right arrow Articles by Ertl, G.
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1539.)
© 2006 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Atheroprotective Effects of Neuronal Nitric Oxide Synthase in Apolipoprotein E Knockout Mice

Peter J. Kuhlencordt; Stefanie Hötten; Johannes Schödel; Sebastian Rützel; Kai Hu; Julian Widder; Alexander Marx; Paul L. Huang; Georg Ertl

From Medizinische Klinik I (P.J.K., S.H., J.S., S.R., K.H., J.W., G.E.), Cardiovascular Center and Department of Pathology (A.M.), University Wuerzburg, Germany; Division of Cardiology (P.L.H.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass.

Correspondence to Peter J. Kuhlencordt, MD, University Hospital Wuerzburg, Department of Medicine, Josef Schneider Str. 2, D97080 Wuerzburg, Germany. E-mail kuhlencord_p{at}klink.uni-wuerzburg.de


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— All 3 isoforms of the nitric oxide synthase (NOS) are expressed in atherosclerotic lesions. To test whether neuronal NOS (nNOS) deficiency affects atherosclerosis, we studied apoE/nNOS{alpha} double knockout (DKO) and apolipoprotein E (apoE) knockout (KO) control mice.

Methods and Results— Lesion area was significantly increased in male DKO (66%) mice after 14 weeks and in female DKO animals (31%) after 24 weeks of "western" diet. Moreover, mean arterial blood pressure was significantly reduced in female DKO animals. Immunohistochemistry revealed nNOS expression in the neointima of KO mice. In DKO animals, residual nNOS staining was caused by the presence of nNOS splice variants. Whereas nNOS{alpha} was present in vessels of KO and absent in DKO animals, nNOS{gamma} was expressed in KO and DKO mice.

Conclusion— nNOS{alpha} protects against atherosclerosis as nNOS{alpha} deletion leads to an increase in plaque formation in apoE/nNOS{alpha} DKO mice. Female DKO mice showed a significant reduction in mean arterial blood pressure. Additionally, we found expression of nNOS splice variants in vessels of apoE KO mice. Our data highlights nNOS{alpha} overexpression as a potential therapeutic strategy and naturally occurring splice variants that lack exon 2 of the nNOS gene as a potential risk factor for vascular disease.

Here we test whether neuronal NOS (nNOS) deficiency affects atherosclerosis in apoE/nNOS{alpha} double knockout (DKO) and apoE knockout animals. Male and female DKO animals showed a significant increase in lesion-area. Thus, nNOS{alpha} protects against atherosclerosis. Female but not male DKO mice showed a significant reduction in mean arterial blood pressure.


Key Words: nitric oxide • nitric oxide synthase • arteriosclerosis • blood pressure • gene expression


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Neuronal nitric oxide synthase (nNOS) is expressed in early and advanced human atherosclerotic lesions.1 Immunolocalization and in situ hybridization revealed nNOS expression in endothelial cells, macrophages, and smooth muscle cells. In addition, nNOS expression is found in perivascular nitrinergic neurons.2–4 Although nNOS and endothelial nitric oxide synthase (eNOS) are termed constitutive NOS isoforms, nNOS is only detectable in intact human vessels using supersensitive methods, suggesting that expression may be induced in atherosclerosis.1,5 The nNOS gene produces multiple mRNA splice variants through various mechanisms, namely alternate promotor usage, alternative splicing, cassette insertion and deletions, and varied sites of 3'-UTR cleavage and polyadenylation.6 These mechanisms lead to 4 different peptides, of which 2 have a PDZ domain that anchors them to the sarcoplasmic reticulum, whereas 2 lack the PDZ-domain, localizing them to the cytosol.6 Schwarz et al reported the presence of small amounts of brain-type nNOS{alpha} and muscle-type nNOSµ in the media and adventitia of rat aorta and showed that nNOS may exert an inhibitory effect against a vasoconstrictive response.7 Recent studies in a mouse carotid artery ligation model, as well as a rat model of balloon induced vascular injury, demonstrated that nNOS is expressed after vascular injury and inhibits intima proliferation, pointing toward a vasculoprotective role of nNOS.8 So far, the relevance of nNOS expression in spontaneous plaque formation has not been addressed. To study the relative contribution of nNOS to lesion formation, we combined a genetic model of chronic nNOS{alpha} deficiency (nNOS KO) with a mouse model of atherosclerosis, the hypercholesterolemic apolipoprotein E (apoE) KO mouse. ApoE KO mice develop progressive endothelial dysfunction which is more pronounced in "western" diet-fed animals.9 As previously published, deletion of eNOS leads to a dramatic increase in lesion formation in apoE KO atherosclerosis.10 Whereas eNOS deletion gave rise to an array of vascular complications including abdominal aneurysms, aortic dissections, and ischemic heart disease, deletion of the inducible NOS (iNOS) decreased atherosclerosis and plasma levels of lipid peroxides in apoE KO animals.11 The latter suggests that iNOS-derived NO formation is proatherogenic, partly through increasing oxidative stress.11 The current study tests the hypothesis that nNOS expression in atherosclerotic lesions inhibits plaque progression. In this case, genetic deficiency of nNOS would accelerate atherosclerosis. Additionally, we studied gender dependence of lesion formation, the influence of nNOS deletion on blood pressure regulation, and the expression of nNOS splice variants in atherosclerotic plaques.

See page 1417


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
All procedures performed conformed with the policies of the University of Würzburg, the National Institutes of Health guidelines and an independent governmental committee for care and use of laboratory animals.

Mice
nNOS KO mice were generated by targeted deletion in the laboratory of Paul Huang.12 The mice carry a deletion of the flanking region of exon 2, ablating translational start of the full-length brain-spliced nNOS{alpha}. ApoE KO animals were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). All mice were backcrossed for ten generations to the C57BL/6 strain. nNOS KO and apoE KO animals were crossed to generate double heterozygous mice. From the F2-mating, apoE KO animals heterozygous for nNOS, were selected and the offspring were genotyped for nNOS by southern blotting and apoE using a polymerase chain reaction (PCR) protocol provided by the Jackson Laboratories.12 ApoE KO animals, wild-type or KO for nNOS, were weaned and started on a Western diet (42% of total calories from fat; 0.15% cholesterol; Harlan Teklad) at 6 weeks of age and for a period of 14 or 24 weeks.

Lesion Assessment
The aorta was dissected and analyzed as previously described.10,11 Animals were anesthetized with pentobarbital (80 µg/kg intraperitoneal), the aorta was perfused with phosphate-buffered saline (pH 7.4) and dissected from the aortic valve to the iliac bifurcation. Adventitial tissue was removed and the aorta was opened longitudinally and pinned onto a black wax surface using micro needles (Fine Science Tools). Serial images of the submerged vessels were captured with a black and white video camera (COHU) mounted on a stereomicroscope (Leica). Lipid-rich intraluminal lesions were stained with Sudan IV. Serial color pictures were captured using the same microscope equipped with a Leica 35-mm camera and used to identify lesions. Image analysis was performed using Image Pro Plus (Version 4.1; Media Cybernetics). The amount of aortic lesion formation in each animal was measured as percent lesion area per total area of the aorta.

Tissue Preparation and Histology
The animals were anesthetized with pentobarbital (80 µg/kg intraperitoneal) and perfused with 0.9% NaCl using a catheter placed in the left ventricle. For histochemistry and immunohistochemistry, tissue of 3 apoE KO and 3 apoE/nNOS DKO animals was embedded in Tissue-Tek® (Sakura Finetek) and snap-frozen in liquid nitrogen (LN2). Serial sections were taken from the aortic valve and aortic arch and fixed in acetone before staining. Sections were stained with hematoxylin/eosin (H&E), Masson’s trichrome and Picric acid. Immunostaining was performed using a monoclonal anti-{alpha} smooth muscle actin antibody (clone 1A4; Sigma) and a mouse macrophage/monocyte monoclonal antibody (MOMA-2; Chemicon International) A polyclonal anti-nNOS antibody (BD Biosciences) was used on paraffin sections.

Histomorphometry
Photomicrographs of the aortic valve and aortic arch were taken with a Leitz-Camera mounted on a light microscope (Carl-Zeiss, Jena, Germany). Pictures were digitalized and transferred to a personal computer for planimetry using Image Pro Plus (Version 4.1; Media Cybernetics). All images were analyzed at 100-fold magnification. Areas of positive staining for smooth muscle cells (SMCs), macrophages (n=3 apoE/nNOS DKO and 3 apoE KO mice, respectively), and collagen (Picric acid staining, n=4 apoE/nNOS DKO and apoE KO mice) were measured in multiple plaques per animal and results were expressed as percent positive staining plaque area.

Reverse-Transcription PCR
First-strand cDNA was synthesized from 2 µg of total aortic RNA using random primers (Fermentas). PCR amplification was performed for 35 cycles at primer annealing temperature of 56°C. A 240-bp fragment of DNA encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control (sense primer: 5'-TGA TGA CAT CAA GAA GGG GGA A-3'; antisense primer: 5'-TCC TTG GAG GCC ATG TGG GC CAT-3'). Published primers for splice variants were used as indicated or designed according to known cDNA sequences of nNOS variants.13 A 553-bp nNOS{alpha} fragment was amplified using sense: 5'-ATT AGG ATC CCT TTA CAT CAC ACC TGG AGA CCA-3' and antisense: 5'-ATT ATT CGA AGA CTG TTC GTT CTC TGA ATA CGG-3' primers. A 387-bp nNOSß fragment was amplified using sense: 5'-GTG AAC AGC GTG ATC CAC AG-3' and antisense: 5'-GAC ATC TTC TGA CTT CCG TAT GTG-3'.13 A 159-bp nNOS{gamma} fragment was amplified with sense: 5'-CCC CAG CCA CCT TGC CTT-3' and antisense: 5'-GAC TGT TCG TTC TCT GAA TAC GG-3' primers.13 A 527-bp nNOS-µ was amplified with sense: 5'-GTC TTC CAC CAG GAG ATG-3' and antisense 5'-ACC AGA CTG TGG GCT TCA GA-3'.14 PCR fragments were analyzed by agarose gel electrophoresis.

Quantification of nNOS mRNA
mRNA expression of nNOS{alpha} and nNOS{gamma} variants was quantified by real-time PCR (iCycler; Bio-Rad Laboratories). PCR amplification was performed for 40 cycles at primer annealing of 60°C. nNOS expression was normalized to HPRT signal. nNOS-{alpha} sense: 5'-CCC ACC AAA GCT GTC GAT CT-3' and antisense: 5'-GGA GGT TGG CCT TGG TAT TT. nNOS-{gamma} sense: 5'-CAC CTT GCC TTC CAG AGA CCT-3' and antisense: 5'-GAC TGT TCG TTC TCT GAA TAC GG-3'. HPRT sense: 5'-GTT GGA TAC AGG CCA GAC TTT GT and antisense: 5'-CCA CAG GAC TAG AAC ACC TGC. Fluorogenic probes for nNOS-{alpha}: 5'-6FAM-CAC ACC ATT AGC CTG GGA GAC TGA GCC-DB; nNOS-{gamma}: 5'-6FAM-CCC CAC AGA TCA TTG AAG ACT: CGA TCA T-TMR; HPRT: 5'-6FAM-CTC GTA TTT GCA GAT TCA ACT TGC GC (TIB Molbiol, Germany) were used.

Western Blot Analysis
Aortas were dissected and samples were snap-frozen in LN2. Western blots were performed using a polyclonal anti-eNOS antibody (1:200; BD 30020; Becton Dickinson) and anti-iNOS antibody (1:200; sc-650; Santa Cruz). To confirm equal loading of protein, an anti-actin antibody (sc-8432; Santa Cruz Biotechnologies) was used.

Blood Pressure Measurements
Mice were intubated and ventilated with a rodent respirator (stroke volume 250 µL, rate 90 minutes–1). The common carotid artery was cannulated and a Millar catheter (1.4 F) was advanced into the left ventricle. Blood pressure was recorded under light isoflurane anesthesia.

Lipids and Lipoprotein Characterization
Lipoprotein cholesterol distribution of plasma samples was evaluated after fractionation by fast protein liquid (FPLC) gel filtration. Plasma (200 µL) was fractionated on 2 serial superose-6 columns using an {Delta}kta-FPLC (Amersham Pharmacia Biotech) system. Total cholesterol of plasma samples and fast protein liquid chromatography fractions were measured using Sigma kit 352 and a Spectra MAX 250 photometer (Molecular Devices).

Statistical Analysis
Two-way ANOVA was used for repeated measures, followed by Scheffe F test (Stat View 4.51; Abacus Concepts Inc, Berkley, Calif). P≤0.05 was considered significant. Student t test was used for unpaired data. Survival of diet-fed animals was expressed by the Kaplan Meier method and survival curves were compared by the log-rank test (Prism 3; GraphPad Software Inc, San Diego, Calif).


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Inspection of the "en face" dissected aortas revealed that apoE KO and apoE/nNOS DKO animals develop atherosclerotic lesions in areas of disrupted laminar flow, namely in areas of branching off vessels and curvature (Figure 1). Atherosclerotic lesions of "western" diet-fed apoE KO animals stained nNOS-positive by immunohistochemistry, documenting that nNOS is present in lesions after 14 weeks of diet (Figure 2). However, plaques from apoE/nNOS DKO animals revealed residual nNOS staining (Figure 2). Reverse-transcription PCR from total aortic RNA documented the presence of nNOS{alpha} variant in C57BL6 and apoE KO vessels and its absence in apoE/nNOS DKO mice (Figure 3). In contrast, the nNOS{gamma} variant was present in vessels from C57BL6, apoE KO, and apoE/nNOS DKO mice, whereas the nNOSß and nNOSµ variant were not detectable in either group. Real-time PCR revealed low but equal expression of nNOS{alpha} in C57BL6 and apoE KO mice and nNOS{gamma} in vessels from all 3 genotypes (Figure 3). After 14 weeks of "western" diet, lesion area in male apoE/nNOS DKO animals (15.56±1.14%, n=10) showed a 66% increase compared with lesions in apoE KO control animals (9.35±1.32%, n=9, P=0.002; Figure 4a). Lesion area in female apoE/nNOS DKO (15.08±0.85%, n=11) and apoE KO animals (12.63±0.7%, n=12, P=0.31) (Figure 4a) did not differ at this time point. However, after 24 weeks of "western" diet, female animals showed a significant 31% increase in lesion area (apoE/nNOS DKO: 31.8±2.3%, n=9; apoE KO: 24.26±1.1%, n=13, P=0.033) (Figure 4b), whereas the increase in lesion area in male animals did not reach statistical significance (apoE/nNOS DKO: 31.64±3.5%, n=11; apoE KO: 24.89±3.5%, n=8, P=0.63). Kaplan Meier analysis revealed a pronounced increase in mortality of DKO animals by log rank test comparison of survival curves (apoE KO: n=31, apoE/nNOS DKO: n=42; P=0.0003). The increase in mortality in apoE/nNOS DKO mice affected male and female animals and was only present after 24 weeks of "western" diet (Figure 4c).


Figure 1
View larger version (21K):
[in this window]
[in a new window]
  		Figure 1. Sudan IV-stained, longitudinally opened aortas from female apoE KO (KO) and apoE/nNOS DKO (DKO) animals fed a "western" diet for 24 weeks. Luminal side facing up, displaying lipid rich (red) atherosclerotic lesions.


Figure 2
View larger version (115K):
[in this window]
[in a new window]
  		Figure 2. Immunohistochemical staining for nNOS (left, upper row) of an aortic root lesion from an apoE KO animal. Second antibody alone, revealing no background staining (right, upper row). nNOS staining of the common carotid artery of apoE KO (left, lower row) compared with apoE/nNOS DKO mice (right, lower row) showing residual nNOS immunoreactivity in DKO animals.


Figure 3
View larger version (18K):
[in this window]
[in a new window]
  		Figure 3. RT-PCR for nNOS splice variants showing expected products for nNOS{alpha}, ß, {gamma}, and µ in control RNA. apoE KO aortas express nNOS{alpha} and nNOS{gamma} variants, whereas nNOSß and nNOSµ are absent. In apoE/nNOS DKO aortas only nNOS {gamma} is expressed. Real-time PCR reveals equal nNOS{alpha} expression in C57BL6 and apoE KO mice (upper box blot) and of nNOS{gamma} in C57BL6, apoE KO, and apoE/nNOS DKO mice (lower box blot).


Figure 4
View larger version (16K):
[in this window]
[in a new window]
  		Figure 4. Mean lesion area expressed as percent lesion area of total area of the aorta at 14 weeks (a; male and female) and 24 weeks (b; female). *Significant difference (P≤0.05). Kaplan Meier survival curve (c) of "western" diet fed apoE KO (n=31) and apoE/nNOS-DKO (n=42) animals showing a pronounced decrease in late survival of apoE/nNOS DKO animals (P=0.0003).

At both time points, total aortic area and total body weight did not differ between animals of either genotype. In addition, total plasma cholesterol (Table) and FPLC analysis of lipoprotein profiles (data not shown) did not differ among study groups.


View this table:
[in this window]
[in a new window]
  		Characteristics of apoE KO and apoE/nNOS DKO Mice

Interestingly, mean arterial blood pressure of female apoE/nNOS DKO animals was significantly reduced compared with control apoE KO animals (apoE/nNOS DKO: 84.1±2.73 mm Hg, n=9; apoE KO: 96.8±2.3 mm Hg, n=10, P=0.013), whereas blood pressure in male animals of both genotypes did not differ (Table). To rule out that nNOS deletion modulated expression levels of iNOS or eNOS, Western blot analysis was performed. eNOS protein was present in both genotypes at comparable levels. The iNOS protein level in female mice was higher compared with male animals, but no difference was observed between the 2 genotypes (Figure I, available online at http://atvb.ahajournals.org).

To check for differences in plaque composition, serial cryosections were taken from the aortic valve area and aortic arch and used for histochemistry and immunohistochemistry. All groups of animals studied developed complex lesions with a variable necrotic core and content of fibrous tissue (Figure IIa and IIb, available online at http://atvb.ahajournals.org). No statistical difference of picric acid positive areas between animals of the same gender but different genotype was observed (apoE/nNOS DKO: 38.2% ±2.1 SE, n=19 plaques; apoE KO: 38.0% ±2.7 SE, n=19 plaques, P=0.94). In addition, plaques displayed strong immunoreactivity for macrophages without a gross difference between the groups (apoE/nNOS DKO: 46.4% ±2.6 SE, n=14 plaques; apoE KO: 49.7% ±3.9 SE, n=19 plaques, P=0.53; Figure IIa and IIb). Staining for vascular SMCs revealed a high degree of variability within each animal, regardless of the experimental groups. However, the strongest {alpha}SMC-actin staining was seen in apoE/nNOS DKO animals (apoE/nNOS DKO: 11.4% ±3.1 SE, n=18 plaques; apoE KO: 6.16% ±0.95 SE, n=14 plaques, P=0.16, Figure IIb and IIc).


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
Nitric oxide has potential atheroprotective effects because it inhibits smooth muscle cell proliferation, leukocyte endothelial interactions, leukocyte adhesion and aggregation of platelets, and endothelial exocytosis of granules that mediate vascular inflammation and thrombosis.15–19 However, NO has proatherogenic properties, because it reacts with superoxide to form peroxinitrite, which can further react to an array of oxygen and nitrogen radicals.20 Moreover, each NOS isoform is capable of generating superoxide under conditions of substrate and cofactor deficiency.21–24 To dissect the role of each isoform in lesion formation, we generated apoE/NOS DKO mice to test the relevance of the absence of each isoform on lesion development. Our previously published results show that eNOS is atheroprotective, and apoE/eNOS DKO animals developed a dramatic increase in lesion formation.10 In contrast, genetic deficiency of iNOS decreases atherosclerosis and lowers plasma lipid peroxides, a marker of oxidative stress, in apoE KO animals.11

In the present study we demonstrate that genetic deficiency of nNOS accelerates atherosclerotic lesion progression. The location of lesions was similar in apoE KO control and apoE/nNOS DKO animals. Western blot analysis revealed higher iNOS expression in female compared with male animals. However, iNOS expression levels in the female and the male group were similar and do not explain the differences in lesion formation within these gender groups. eNOS expression levels were equal in all experimental groups.

Lesion progression was significantly accelerated in male apoE/nNOS DKO compared with male apoE KO animals after 14 weeks of western-type diet. In female apoE/nNOS DKO mice, there was a significant increase in plaque area after 24 weeks of western diet. After 24 weeks of diet, however, the increase in lesion area in male apoE/nNOS DKO animals did not reach statistical significance, which may be explained by a higher mortality in apoE/nNOS DKO mice at this time point (Figure 4c).

The slower increase in lesion area in female apoE/nNOS DKO compared with male apoE/nNOS DKO animals was associated with a reduction in mean arterial blood pressure in female DKO mice. Because blood pressure elevation is an independent risk factor for atherosclerosis, the reduced blood pressure in female DKO animals renders a possible explanation for the delayed lesion progression in this group.

The reduction in blood pressure in female animals is not likely to occur at the level of the vessel wall because vascular nNOS would likely cause vasodilation and thus nNOS deletion would be expected to raise the blood pressure.7 Instead, nNOS deletion could affect blood pressure regulation in the central nervous system, at the level of the baroreceptors, or through endocrine mechanisms. In this respect, NO, regardless of its source, is known to be involved in the regulation of renin secretion.25 Whereas acute inhibition of nNOS does not seem to affect blood pressure, chronic pharmacological inhibition of nNOS using 7-nitroindazole (7-NI) significantly increased blood pressure in one study.26–28 In contrast, acute and chronic nNOS inhibition in eNOS KO animals caused a decrease in blood pressure, which may be caused by nNOS-dependent mechanisms at the level of the central nervous system or the baroreceptor pathway.29 And although nNOS KO animals were reported to have a tendency toward hypotension, gender differences in nNOS-dependent blood pressure regulation have not been reported so far.30,31

To evaluate potential differences in plaque composition, we stained lesions by immunohistochemistry and histochemistry. Animals of both genotypes developed complex lesions with fibrous caps and necrotic cores. Both genotypes showed strong immunoreactivity for macrophages without an obvious difference between groups. Lesions with the strongest alpha smooth muscle actin staining were seen in apoE/nNOS DKO animals (Figure IIa and IIb). In the past, NO has been shown to suppress smooth muscle cell proliferation.18 Recent data indicated that angiotensin can induce nNOS expression in vascular smooth muscle cells and that this nNOS expression is sufficient to suppress SMC proliferation in vitro.8 However, neointimal alpha smooth muscle actin staining in our study was highly variable between animals and even among lesions within each mouse (Figure IIc), preventing statistical significance of our observation. The occurrence of plaques in apoE/nNOS DKO mice that lack any SMC staining suggests that the absence of nNOS does not by itself trigger SMC proliferation. Instead, the occurrence of pronounced SMC proliferation in single plaques of apoE/nNOS DKO mice let us speculate that nNOS serves to counterbalance local and systemic factors that would foster SMC proliferation.

It is important to note that nNOS{alpha} (exon 2) KO animals used in this study express nNOSß and nNOS{gamma} mRNA splice variants in brain tissue by using alternate translation start sites.13 Therefore, we investigated whether nNOS splice variants are present in vessels of C57BL6, apoE KO, and apoE/nNOS DKO animals. We find residual nNOS immunoreactivity in the neointima of apoE/nNOS DKO mice and similarly low expression levels of the nNOS{gamma} splice variant in aortas of C57BL6, apoE KO, and apoE/nNOS DKO animals. The N-terminal truncated nNOS{gamma} variant lacks the PDZ domain and is localized to the cytosolic fraction.13 In vitro assays indicate that nNOS{gamma} has low catalytic activity (3% of nNOS{alpha}), whereas nNOSß possesses activity comparable to nNOS{alpha}.13 However, nNOSß and nNOSµ variants were not detectable in mouse aortas in our study. Our study differs from a study by Schwartz et al who reported the presence of small amounts of nNOSµ in the media and adventitia of intact rat aorta and the study by Morishita et al, who reported absence of nNOS expression in carotid arteries of untreated C57BL6 mice.7,8 These latter differences may be explained by the use of different species, the study of the arteria carotis versus the aorta and the use of injury models as opposed to a model of spontaneous arteriosclerosis. The nNOS KO animals used in this study are not expected to have membrane targeted nNOS expression caused by deletion of the PDZ targeting motif contained in exon 2. Interestingly, splice variants that lack exon 2 are reported to occur spontaneously in mice, rats, and humans.13,32,33 Our data highlight nNOS{alpha} overexpression as a potential therapeutic strategy. Moreover, the prevalence of splice variants that lack exon 2 of the nNOS gene within each individual may be a risk factor for vascular disease.

In summary, we provide first evidence for the presence of nNOS splice variants in atherosclerotic vessels and show that genetic deficiency of nNOS{alpha} increases atherosclerosis development in apoE KO animals. Therefore, our study indicates that nNOS{alpha} protects from atherosclerosis. In addition, systemic blood pressure was reduced in female apoE/nNOS DKO mice and nNOS deletion led to a significant increase in mortality in DKO animals.


*    Acknowledgments
 
We thank Gabriele Riehl and Alla Ganscher for excellent technical assistance.

Source(s) of Funding

This work was supported by grants from the Deutsche-Forschungsgemeinschaft [KU-1206(1) and 1206(2) to P.K.] and the IZKF-Würzburg (E-30 to P.K.), the National Institute of Neurological Disorders and Stroke (NINDS, NS33335), and the National Heart, Lung, and Blood Institute (NHLBI, HL57818 to P.L.H.). P.L.H. is an Established Investigator of the American Heart Association.

Disclosure(s)

None.


*    Footnotes
 
Original received November 28, 2005; final version accepted April 7, 2006.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997; 17: 2479–2488.[Abstract/Free Full Text]
  2. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990; 347: 768–770.[CrossRef][Medline] [Order article via Infotrieve]
  3. Kulkarni AP, Getchell TV, Getchell ML. Neuronal nitric oxide synthase is localized in extrinsic nerves regulating perireceptor processes in the chemosensory nasal mucosae of rats and humans. J Comp Neurol. 1994; 345: 125–138.[CrossRef][Medline] [Order article via Infotrieve]
  4. Nozaki K, Moskowitz MA, Maynard KI, Koketsu N, Dawson TM, Bredt DS, Snyder SH. Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab. 1993; 13: 70–79.[Medline] [Order article via Infotrieve]
  5. Buchwalow IB, Podzuweit T, Bocker W, Samoilova VE, Thomas S, Wellner M, Baba HA, Robenek H, Schnekenburger J, Lerch MM. Vascular smooth muscle and nitric oxide synthase. FASEB J. 2002; 16: 500–508.[Abstract/Free Full Text]
  6. Wang Y, Newton DC, Marsden PA. Neuronal NOS: gene structure, mRNA diversity, and functional relevance. Crit Rev Neurobiol. 1999; 13: 21–43.[Medline] [Order article via Infotrieve]
  7. Schwarz PM, Kleinert H, Forstermann U. Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol. 1999; 19: 2584–2590.[Abstract/Free Full Text]
  8. Morishita T, Tsutsui M, Shimokawa H, Horiuchi M, Tanimoto A, Suda O, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y. Vasculoprotective roles of neuronal nitric oxide synthase. FASEB J. 2002; 16: 1994–1996.[Abstract/Free Full Text]
  9. Yang R, Powell-Braxton L, Ogaoawara AK, Dybdal N, Bunting S, Ohneda O, Jin H. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 1999; 19: 2762–2768.[Abstract/Free Full Text]
  10. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001; 104: 448–454.[Abstract/Free Full Text]
  11. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001; 103: 3099–3104.[Abstract/Free Full Text]
  12. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell. 1993; 75: 1273–1286.[CrossRef][Medline] [Order article via Infotrieve]
  13. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, Froehner SC, Bredt DS. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 1996; 84: 757–767.[CrossRef][Medline] [Order article via Infotrieve]
  14. Silvagno F, Xia H, Bredt DS. Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem. 1996; 271: 11204–11208.[Abstract/Free Full Text]
  15. Lefer AM, Ma XL, Weyrich A, Lefer DJ. Endothelial dysfunction and neutrophil adherence as critical events in the development of reperfusion injury. Agents Actions Suppl. 1993; 41: 127–135.[Medline] [Order article via Infotrieve]
  16. Bath PM. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol. 1993; 45: 53–58.[CrossRef][Medline] [Order article via Infotrieve]
  17. Radomski MW, Palmer RM, Moncada S. Modulation of platelet aggregation by an L-arginine-nitric oxide pathway. Trends Pharmacol Sci. 1991; 12: 87–88.[CrossRef][Medline] [Order article via Infotrieve]
  18. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 1995; 25: 674–678.[Medline] [Order article via Infotrieve]
  19. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O’Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003; 115: 139–150.[CrossRef][Medline] [Order article via Infotrieve]
  20. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271: C1424–C1437.
  21. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998; 273: 25804–25808.[Abstract/Free Full Text]
  22. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci U S A. 1997; 94: 6954–6958.[Abstract/Free Full Text]
  23. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem. 1998; 273: 22635–22639.[Abstract/Free Full Text]
  24. Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992; 281: 627–630.
  25. Castrop H, Schweda F, Mizel D, Huang Y, Briggs J, Kurtz A, Schnermann J. Permissive role of nitric oxide in macula densa control of renin secretion. Am J Physiol Renal Physiol. 2004; 286: 848–857.
  26. Pajewski TN, DiFazio CA, Moscicki JC, Johns RA. Nitric oxide synthase inhibitors, 7-nitro indazole and nitroG-L-arginine methyl ester, dose dependently reduce the threshold for isoflurane anesthesia. Anesthesiology. 1996; 85: 1111–1119.[CrossRef][Medline] [Order article via Infotrieve]
  27. Zanzinger J, Czachurski J, Seller H. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. Circ Res. 1997; 80: 565–571.[Abstract/Free Full Text]
  28. Ollerstam A, Pittner J, Persson AE, Thorup C. Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest. 1997; 99: 2212–2218.[Medline] [Order article via Infotrieve]
  29. Kurihara N, Alfie ME, Sigmon DH, Rhaleb NE, Shesely EG, Carretero OA. Role of nNOS in blood pressure regulation in eNOS null mutant mice. Hypertension. 1998; 32: 856–861.[Abstract/Free Full Text]
  30. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994; 265: 1883–1885.[Abstract/Free Full Text]
  31. Wang T, Inglis FM, Kalb RG. Defective fluid and HCO(3)(-) absorption in proximal tubule of neuronal nitric oxide synthase-knockout mice. Am J Physiol Renal Physiol. 2000; 279: F518–F524.[Abstract/Free Full Text]
  32. Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci U S A. 1997; 94: 3396–3401.[Abstract/Free Full Text]
  33. Wang Y, Newton DC, Robb GB, Kau CL, Miller TL, Cheung AH, Hall AV, VanDamme S, Wilcox JN, Marsden PA. RNA diversity has profound effects on the translation of neuronal nitric oxide synthase. Proc Natl Acad Sci U S A. 1999; 96: 12150–12155.[Abstract/Free Full Text]

Related Article:

Beneficial Effects of Neuronal Nitric Oxide Synthase in Atherosclerosis
Charles J. Lowenstein
Arterioscler. Thromb. Vasc. Biol. 2006 26: 1417-1418. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
G. Lim, L. Venetucci, D. A. Eisner, and B. Casadei
Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling
Cardiovasc Res, January 15, 2008; 77(2): 256 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
V. W.T. Liu and P. L. Huang
Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice
Cardiovasc Res, January 1, 2008; 77(1): 19 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Nakata, M. Tsutsui, H. Shimokawa, T. Yamashita, A. Tanimoto, H. Tasaki, K. Ozumi, K. Sabanai, T. Morishita, O. Suda, et al.
Statin Treatment Upregulates Vascular Neuronal Nitric Oxide Synthase Through Akt/NF-{kappa}B Pathway
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 92 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. J. Lowenstein
Beneficial effects of neuronal nitric oxide synthase in atherosclerosis.
Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1417 - 1418.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/7/1539    most recent
01.ATV.0000223143.88128.19v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuhlencordt, P. J.
Right arrow Articles by Ertl, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuhlencordt, P. J.
Right arrow Articles by Ertl, G.
Related Collections
Right arrowRelated Article

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.